Amitriptyline: Nursing Drug Guide, Suicidality & Cardiac Risk
Healthcare medication guide: antidepressant suicidality surveillance during initiation and dose changes, TCA cardiac arrhythmia and overdose toxicity, and anticholinergic burden in older adults—before sedation or dry mouth feel routine.
Amitriptyline carries a boxed warning that antidepressants increase suicidal thinking and behavior in children, adolescents, and young adults compared with placebo. Monitor all patients—especially during the first months and at dose changes—for worsening depression, suicidality, agitation, and unusual behavior. TCA overdose can cause fatal dysrhythmias, severe hypotension, seizures, and coma; obtain an ECG immediately when toxicity is suspected. Older adults are especially sensitive to anticholinergic effects (confusion, falls, urinary retention). Do not give with MAO inhibitors—allow at least 14 days after MAOI discontinuation before starting amitriptyline.
📋 Contents
⚡ Quick facts
💡 Key takeaway
On every shift after a new start or dose change, assess mood, behavior, and safety—not only sedation or anticholinergic comfort. If overdose is possible, treat it as a cardiac emergency: ECG now, continuous monitoring, and poison control or toxicology per facility protocol—not “wait for symptoms.”
Most common brand names
Amitriptyline hydrochloride is supplied as oral tablets (commonly 10, 25, 50, 75, 100, and 150 mg). Verify the exact product on the MAR and pharmacy label.
Common brand names include Elavil and Endep. Because TCAs are sedating, bedtime dosing is frequent—do not confuse a “sleep dose” with a subtherapeutic antidepressant plan without prescriber clarification.
Why we give it — Indications
Prescribing information lists amitriptyline for relief of symptoms of depression; endogenous depression is more likely to respond than other depressive states. In practice, clinicians also use TCAs off-label for neuropathic pain, migraine prophylaxis, and insomnia at low doses—nurses should know the indication on the order because monitoring emphasis shifts (suicidality surveillance remains essential whenever used as an antidepressant).
| Use | Detail |
|---|---|
| Major depression | Label indication; therapeutic effect may take up to 30 days to develop; sedative effect may appear earlier |
| Adjunct / low-dose uses | Institutional protocols may use lower bedtime doses for pain or sleep—confirm indication and target symptoms with the prescriber |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Amitriptyline is an antidepressant with sedative effects; its mechanism in humans is not fully known. It is not a monoamine oxidase inhibitor and does not act primarily by CNS stimulation. It inhibits reuptake of norepinephrine and serotonin in adrenergic and serotonergic neurons, prolonging neuronal activity. TCAs also have significant anticholinergic, antihistaminic, and alpha-blocking properties—driving dry mouth, sedation, orthostasis, and cardiac conduction effects nurses must anticipate.
Dosing overview
Initiate at a low dose and increase gradually while watching for intolerance and suicidality warnings. Maximum recommended human dose in labeling is 150 mg/day (or 3 mg/kg/day for a 50 kg patient). Verify orders against current prescribing information and renal/hepatic status.
Maintenance: Usual maintenance 50–100 mg/day; some patients do well on 40 mg/day. After improvement, reduce to the lowest dose that maintains relief; continue maintenance at least 3 months to lessen relapse risk per labeling.
Missed dose: Not specified in the reviewed prescribing information. Do not double doses; contact prescriber or pharmacist if multiple doses are missed, especially after dose increases.
Onset, peak, duration, and half-life
| Parameter | Value | Nursing relevance |
|---|---|---|
| Onset (sedation) | Sedative effect may precede antidepressant effect | Do not assume early sedation means full therapeutic response |
| Antidepressant effect | May take up to 30 days | Continue suicidality monitoring throughout the titration period |
| Plasma levels | Wide absorption/metabolism variation; levels difficult to correlate with effect | Elderly often have higher levels for a given oral dose—monitor clinically |
| Half-life | Not specified in nursing summary of reviewed labeling | Active metabolite nortriptyline contributes to effects—interaction profile persists after parent drug changes |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
Pretreatment checks
- Screen for bipolar disorder history before treating depressive symptoms with antidepressant alone
- Review cardiovascular history (heart failure, recent MI, arrhythmia), seizure history (epilepsy), narrow-angle glaucoma, urinary retention, and fall risk
- Confirm no MAOI within 14 days; reconcile SSRIs and other serotonergic agents via medication reconciliation
- Assess baseline mood, sleep, and safety plan; involve family/caregivers per Medication Guide counseling
Contraindications
- Hypersensitivity to amitriptyline
- Concomitant MAO inhibitors (minimum 14-day washout when switching from MAOI)
- Concomitant cisapride (QT prolongation risk)
- Acute recovery phase after myocardial infarction
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| MAO inhibitors (including linezolid) | Hyperpyretic crises, severe convulsions, deaths reported with TCA + MAOI | Hold amitriptyline; verify 14-day MAOI washout; pharmacist review before restart |
| SSRIs (fluoxetine, sertraline, paroxetine) | Inhibit CYP2D6—can raise TCA levels abruptly; fluoxetine needs long washout before starting TCA | Coordinate switches with pharmacy; monitor for toxicity (sedation, confusion, cardiac changes) |
| Other TCAs / sedatives | Additive anticholinergic and CNS depression | Compare with nortriptyline orders; avoid duplicate sedating psychotropics without prescriber intent |
| Anticholinergics | Paralytic ileus, hyperpyrexia, worsening urinary retention and confusion | Monitor bowel, temperature, mental status; hold and clarify if ileus symptoms develop |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Route: Oral tablet. Many regimens give the largest portion at bedtime because of sedation.
- Swallow tablets whole unless pharmacy approves splitting/crushing for a specific formulation
- Protect from light; store at controlled room temperature in a well-closed, light-resistant container per labeling
- Counsel that hazardous tasks (driving, machinery) may be impaired until response is known
Observe closely for clinical worsening, suicidality, and unusual behavior when therapy starts and whenever dose changes—especially in young adults. Report emergent anxiety, insomnia, irritability, hostility, akathisia, hypomania, or mania to the prescriber immediately.
Expected therapeutic response
- Gradual improvement in depressive symptoms over weeks—not immediate like anxiolytics
- Improved sleep when low-dose bedtime use is intended—distinguish sedation from mood recovery
- Stable vitals and ECG without new palpitations, syncope, or conduction abnormalities
Red flags — Stop and act
Escalate urgently for suicidality, cardiac toxicity, or severe anticholinergic compromise.
- New or worsening suicidal ideation, self-harm behavior, or violent impulsivity—immediate prescriber and safety intervention
- Sustained tachycardia, syncope, wide QRS, or ventricular arrhythmia on ECG—suspect TCA toxicity especially with overdose
- Seizures, coma, severe hypotension, or marked mental status change after ingestion or rapid dose escalation
- Paralytic ileus, urinary retention, or hyperpyrexia when combined with anticholinergic drugs
- Acute eye pain or vision changes in patients at risk for angle-closure glaucoma after pupillary dilation from antidepressants
Adverse effects
| Adverse effect | Frequency / severity | Nursing response |
|---|---|---|
| Dry mouth, constipation, urinary retention | Common anticholinergic effects; worse in elderly | Fall precautions, bowel protocol, monitor urine output; notify if retention or ileus |
| Blurred vision, mydriasis | Anticholinergic ophthalmic effects | Assess glaucoma risk; escalate acute eye pain or vision loss |
| Sedation, dizziness, orthostatic hypotension | Common CNS/cardiovascular effects | Rise slowly; night lights; syncope workup if recurrent |
| Arrhythmias, conduction delay, tachycardia | Serious cardiovascular effects at high doses or overdose | ECG when symptomatic or suspected ingestion; continuous monitoring per toxicology |
| Seizures, coma (overdose) | Critical toxicity | Activate emergency response; poison control per protocol |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Deaths may occur from TCA overdose. Toxicity develops rapidly; hospital monitoring is required as soon as possible. Multiple drug ingestion including alcohol is common in deliberate overdose.
Critical manifestations
- Cardiac dysrhythmias, severe hypotension, convulsions, CNS depression including coma
- ECG: QRS widening (≥0.10 s may indicate severity), rightward terminal QRS axis, prolonged QT, sinus tachycardia
- Agitation, hyperactive reflexes, hyperpyrexia, dilated pupils, or anticholinergic signs
Management (nursing priorities)
Obtain ECG and initiate cardiac monitoring immediately. Secure airway, IV access, activated charcoal after airway protection—emesis is contraindicated. Minimum six hours observation with monitoring; extend if toxicity signs appear. Sodium bicarbonate therapy may be used per toxicology for QRS prolongation. Contact local poison control or medical toxicology for current treatment guidance. No single antidote replaces structured toxicology care.
Contact local poison control or medical toxicology services per facility protocol when overdose is suspected. Psychiatric follow-up is often appropriate because overdose may be deliberate.
Look-alike / sound-alike and error prevention
- Amitriptyline vs nortriptyline—both TCAs; different sedating and cardiac profiles; verify active ingredient
- Amitriptyline vs amoxapine / imipramine—sound-alike TCA names on MARs
- Bedtime “sleep dose” vs depression dose—ensure MAR reflects intended indication and total daily milligrams
- Duplicate psychotropics—SSRI plus TCA without washout planning increases toxicity risk
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Timing | Bedtime dosing common when sedation is desired; divided doses may be used for outpatients |
| Abrupt stop | After prolonged use, abrupt stop may cause nausea, headache, irritability—taper per prescriber |
| Surgery | Discontinue several days before elective surgery when possible per labeling |
| Quantity limits | Prescriptions should be the smallest quantity feasible because suicide risk includes overdose |
| Ask pharmacy when | SSRI-to-TCA switches, MAOI history, QRS widening on ECG, or unclear bedtime-only orders |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Children & adolescents | Not approved in pediatric patients; boxed warning for suicidality if considered—balance risk with clinical need |
| Young adults (18–24) | Higher suicidality risk versus placebo in short-term studies—intensify monitoring at initiation and dose changes |
| Older adults | Start low (e.g., 10 mg TID + 20 mg HS); anticholinergic effects and falls predominate; higher plasma levels for same dose |
| Cardiovascular disease | Arrhythmias and conduction delays reported—avoid acute post-MI period; watch vitals and ECG |
| Pregnancy / lactation | Pregnancy category C per labeling—use only if benefit justifies risk; LactMed: excreted in milk—shared decision with prescriber |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Mood, behavior, suicidality, sleep, and functional status at each contact during the first months and after dose changes
- Heart rate, blood pressure, orthostatic symptoms, and ECG when cardiac history or overdose concern exists
- Anticholinergic burden: mental status, bowel function, urine output, temperature, vision changes
Document
- Baseline and follow-up safety assessments, family/caregiver education on warning symptoms
- Dose, time, and patient response; any PRN sedative overlap
- ECG and poison-control consultation when toxicity is suspected
Patient teaching
- Antidepressants may increase suicidal thoughts in some people—seek help immediately for worsening depression, agitation, panic, insomnia, irritability, hostility, or thoughts of self-harm
- Do not stop suddenly without talking to the prescriber; withdrawal symptoms can occur
- Rise slowly from sitting or lying down; avoid alcohol and other sedatives unless approved
- Report dry mouth, constipation, urinary difficulty, palpitations, dizziness, eye pain, or vision changes
- Keep appointments; full antidepressant benefit may take weeks
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- MAOI used within 14 days (including linezolid) or serotonergic switch without pharmacy-approved washout
- Active suicidal plan, overdose ingestion, or emergent mania/psychosis
- Symptomatic wide QRS, unstable arrhythmia, or seizure after recent dose
- Paralytic ileus, urinary retention requiring intervention, or acute angle-closure glaucoma symptoms
- Acute recovery phase post myocardial infarction (contraindicated)
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
TCAs are less common than SSRIs but remain high stakes: a missed suicidality cue or a widened QRS after overdose can be fatal. Build antidepressant safety into admission and home medication teaching—not only once at discharge.
1. Check-before-you-give protocol
- Right patient, drug, dose, route, time—and right indication (depression vs low-dose neuropathic/sleep use)
- MAOI/linezolid history and recent SSRI therapy documented
- Suicidality screen current when initiating or changing dose
- Fall and orthostatic precautions in place for sedating doses
2. High-alert and safety badge
High-risk antidepressant — suicidality boxed warning + fatal overdose toxicityTreat overdose as a monitored cardiac emergency. Limit tablet quantities on discharge per good patient management in labeling.
3. Clinical workflow: hold and question rules
- If a patient on fluoxetine is ordered amitriptyline without a documented washout, hold and call pharmacy—fluoxetine may require at least five weeks before TCA start per labeling
- If family reports new impulsivity or insomnia after dose increase, notify prescriber the same day—may be precursors to suicidality
- Any suspected ingestion with QRS ≥0.10 s or altered mental status triggers ECG monitoring and toxicology consult
4. Critical teach-back questions
- “What mood or behavior changes should you report right away?” (Worsening depression, suicidal thoughts, agitation, insomnia, irritability, unusual behavior.)
- “What should you do if you take more tablets than prescribed?” (Seek emergency care and contact local poison control or toxicology per facility guidance—even without symptoms.)
5. Care coordination
Pharmacist: MAOI washout, SSRI-to-TCA switches, drug level concerns in elderly, and overdose management pathways
Psychiatry / prescriber: Suicidality escalation, bipolar screening failures, and need to discontinue or change antidepressant class
🧠 Quick mental checklist
- Is this a new start, dose increase, or switch from an SSRI or MAOI?
- Any suicidal ideation, agitation, insomnia, or behavioral change since the last dose?
- Heart rate, blood pressure, orthostatics, and ECG if ingestion or cardiac history?
- Anticholinergic load: confusion, constipation, urinary retention, blurred vision?
- If overdose suspected, is monitoring started and poison control contacted per protocol?
Amitriptyline NCLEX practice questions
Practice NCLEX-style clinical judgment practice for amitriptyline using a tabbed case (MAR, labs, vitals, nursing notes), then priority action, cue recognition (SATA), ECG trend interpretation, MAOI washout cloze, ordered documentation steps, and a matrix sorting suicidality versus cardiac versus anticholinergic findings—recognise cues → analyse → prioritise → act → evaluate outcomes.
Select a tab to view MAR, labs, vitals, and nursing note details for this case.
- Amitriptyline 50 mg PO at bedtime — started 3 days ago (dose increased from 25 mg last night)
- Fluoxetine 20 mg PO daily — discontinued 10 days ago per MAR
- Linezolid 600 mg PO q12h — completed course 18 days ago
- Docusate 100 mg PO BID — for constipation
- Admission ECG: sinus rhythm, QRS 0.08 s, QTc 420 ms
- Today 1400 (after reported extra tablets): ECG QRS 0.11 s, sinus tachycardia 118/min
- BMP: sodium 138, potassium 4.0, creatinine 0.9 mg/dL
- No serum TCA level available on panel
- 1030: BP 108/62, HR 88, RR 16, SpO2 98% on room air, temp 36.8 °C
- 1400: BP 92/58, HR 118, RR 18, SpO2 97%, temp 37.1 °C
- Orthostatics: lying BP 110/64 → standing BP 88/54 with dizziness
- 72-year-old on unit for major depression; family at bedside
- 0900: Patient denies suicidal plan; mood “about the same”
- 1330: Restless, irritable, insomnia last night; states “my mind races”
- 1345: Nurse found 6 extra 50 mg tablets missing from blister pack; patient admits taking them “to sleep”
- 1400: Dry mucous membranes, constipation 3 days, assisted ambulation for dizziness
Answer key & rationale
Frequently asked questions
Why does amitriptyline have a boxed warning for suicidality?
Antidepressants, including amitriptyline, increased suicidal thinking and behavior compared with placebo in short-term studies in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders. Patients of all ages starting therapy should be monitored for clinical worsening, suicidality, and unusual changes in behavior, especially during initial months and at dose changes.
How long must a nurse wait after stopping an MAOI before starting amitriptyline?
Amitriptyline is contraindicated with monoamine oxidase inhibitors. When replacing an MAOI with amitriptyline, allow a minimum of 14 days after the MAOI is discontinued before initiating amitriptyline, then titrate cautiously per prescribing information.
What ECG changes suggest TCA overdose toxicity?
Labeling states QRS axis or width changes are clinically significant indicators of tricyclic antidepressant toxicity. A rightward terminal QRS shift with prolonged QT and sinus tachycardia are specific and sensitive for first-generation TCA overdose. Obtain an ECG immediately when overdose is suspected.
Is amitriptyline safe during breastfeeding?
LactMed states milk levels are low and adverse effects in breastfed infants are usually not expected, especially after 2 months of age, though use is scored possible with caution. Rare infant sedation has been reported, including severe sleepiness in a 15-day-old nursed by a mother taking 10 mg daily. Decide with the prescriber whether to continue breastfeeding, change therapy, or intensify infant monitoring—other agents may be preferred for large doses or when nursing a newborn or preterm infant.
Why are older adults at higher risk with amitriptyline?
Geriatric patients are particularly sensitive to anticholinergic effects including tachycardia, urinary retention, constipation, dry mouth, blurred vision, confusion, sedation, and falls. Labeling recommends low starting doses with close observation and cautious dose selection.
References
-
U.S. National Library of Medicine. Amitriptyline hydrochloride tablet — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84600bfc-bcbf-4b37-a575-a6a99e2434fd
-
U.S. Food and Drug Administration. Suicidality in children and adolescents being treated with antidepressant medications.https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-suicidality-children-and-adolescents-being-treated-antidepressant
-
Drugs and Lactation Database (LactMed). Amitriptyline. Bethesda (MD): National Institute of Child Health and Human Development.https://www.ncbi.nlm.nih.gov/books/NBK501174/
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.